Investigator Sponsored Studies
Investigator Sponsored Studies supports independent researchers and their institutions with clinical, observational, and nonclinical research to advance knowledge of serious diseases and improve patient care.
This grant was recently updated
Beta thalassemia and sickle cell disease submissions moved from a closed RFP cycle to rolling acceptance, with concept and protocol decisions expected within 45 days. Vertex added interest in innovative real-world effectiveness and safety studies and is not prioritizing prospective studies using G-CSF as a mobilization agent.
Funder: Vertex Pharmaceuticals
Due Dates: Rolling (Concepts in all five disease areas)
Funding Amounts: Funding and/or drug support; no fixed request cap; overhead generally limited to 35%
Summary: Supports independent clinical, observational, and nonclinical research aligned with Vertex’s scientific interests in serious diseases.
Key Information: Support must go to an organization, not an individual; pain proposals are accepted only in the United States.
Description
Vertex’s Investigator Sponsored Studies (ISS) program supports independent scientists, healthcare providers, other researchers, and their affiliated institutions conducting scientifically rigorous research. The program aims to advance knowledge of disease states, patient populations, and medical treatments, generate valuable scientific or clinical information, and enhance patient care. Vertex does not control investigators’ study concepts, design, conduct, communication, or monitoring.
Support may include funding and/or drug for clinical studies investigating specific interventions, observational research—including epidemiological and outcomes studies—and nonclinical research using Vertex compounds in vitro or in vivo. The program covers cystic fibrosis, pain, beta thalassemia, sickle cell disease, and IgA nephropathy (IgAN), with disease-specific priorities and areas that are not currently prioritized.
